2-乙基-1,1-二氧代-1,2-苯并噻唑-3-酮 | 18712-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-乙基-1,1-二氧代-1,2-苯并噻唑-3-酮
• 英文名称: 2-ethyl-1,2-benzisothiazol-3(2H)-one 1,1-dioxide
• 英文别名: 2-ethyl-2,3-dihydro-1,2-benzisothiazol-3-one-1,1-dioxide；2-ethyl-1,2-benzothiazol-3(2H)-one 1,1-dioxide；N-Ethylimide of o-sulfobenzoic acid；N-ethylsaccharin；2-ethyl-1,1-dioxo-1,2-dihydro-1λ⁶-benzo[d]isothiazol-3-one；2-ethyl-1,1-dioxo-1λ⁶-benz[d]isothiazol-3-one；1,2-Benzisothiazol-3(2h)-one, 2-ethyl-, 1,1-dioxide；2-ethyl-1,1-dioxo-1,2-benzothiazol-3-one
• CAS: 18712-20-4
• 化学式: C₉H₉NO₃S
• 分子量: 211.241
• InChiKey: DQKSIWDBRCCINU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-乙基-1,1-二氧代-1,2-苯并噻唑-3-酮 在 potassium tert-butylate 、 乙酸酐 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 生成 Ethyl 2-cyano-2-(3-cyano-2-ethyl-1,1-dioxo-1,2-benzothiazol-3-yl)acetate
  参考文献：
  名称：

  Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents

  摘要：

  Compounds from two novel series of spirosuccinimides were prepared. Analogs of series 2 possessed a spiro-fused isoindolone moiety while those of series 3 contained a spiro-fused benzisothiazole S,S-dioxide group. These compounds were evaluated as aldose reductase inhibitors (ARI) in vitro by their ability to inhibit glyceraldehyde reduction using a partially purified bovine lens aldose reductase preparation and in vivo as inhibitors of galactitol accumulation in the lens, sciatic nerve, and diaphragm of galactose-fed rats. Many members from the isoindolone series 2, particularly those containing an isoindolone N-methyl moiety, showed good in vitro and in vivo potency. The most potent member, the 6-chloro analog 32, was resolved, and aldose reductase activity was found to reside almost exclusively in the (+)-enantiomer. Compound 32 was approximately equipotent in the sciatic nerve of the galactose-fed rat to other cyclic imide ARI's of similar in vitro activity, namely sorbinil and ADN-138 and also to tolrestat, an acetic acid-based ARI (ED50's 4-8 mg/kg). Compounds from both series, 2 and 3, were also found to lower plasma glucose levels of genetically obese db/db and ob/ob mice with potency similar to that of ciglitazone. However, members from these series failed to lower insulin levels of the ob/ob mouse at the doses tested.

  DOI：

  10.1021/jm00102a016
• 作为产物：
  描述：

  N-Ethyl-1,2-benzisothiazolin-3-on 在 过氧乙酸 、 ruthenium trichloride 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以51.2%的产率得到2-乙基-1,1-二氧代-1,2-苯并噻唑-3-酮
  参考文献：
  名称：

  一种制备糖精的合成方法

  摘要：

  本发明提供一种制备糖精的合成方法，将1,2‑苯并异噻唑啉‑3‑酮类化合物与氧化剂进行氧化反应，氧化剂将1,2‑苯并异噻唑啉‑3‑酮类化合物的硫醚氧化成硫酰胺，得到邻苯甲酰硫酰胺类化合物。与传统的糖精的生产工艺相比，本发明糖精的合成方法具有工艺简单、成本低，分离高效、污染小等优点，更符合绿色化学。

  公开号：

  CN111269195B

文献信息

• N -Substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII
  作者：Jekaterīna Ivanova、Fabrizio Carta、Daniela Vullo、Janis Leitans、Andris Kazaks、Kaspars Tars、Raivis Žalubovskis、Claudiu T. Supuran

  DOI：10.1016/j.bmc.2017.04.007

  日期：2017.7

  well as some ring opened derivatives were prepared and investigated as inhibitors of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). The widespread cytosolic isoforms CA I and II were not inhibited by these sulfonamides whereas transmembrane, tumor-associated ones were effectively inhibited, with KIs in the range of 22.1-481nM for CA IX and of 3.9-245nM for hCA XII. Although the inhibition mechanism

  制备了一系列结合有芳基，烷基和炔基部分的N-取代糖精，以及一些开环衍生物，并作为金属酶碳酸酐酶的抑制剂进行了研究（CA，EC 4.2.1.1）。这些磺胺类药物不会抑制广泛的胞质亚型CA I和II，而与肿瘤相关的跨膜被有效抑制，CA IX的KIs范围为22.1-481nM，hCA XII的KIs范围为3.9-245nM。尽管目前尚不清楚这些叔/仲磺酰胺的抑制机制，但是对于抑制与胞质广泛分布的同工型相关的肿瘤的良好疗效，尤其是选择性，使得这些衍生物作为酶抑制剂具有相当大的兴趣，并具有多种药理应用。
• Regioselective Alkylation of Saccharin with Alcohols under Mitsunobu Conditions
  作者：Xiaolong Wang、Yanying Ma、Tingting Ju

  DOI：10.3184/174751913x13716447161975

  日期：2013.7

  The regioselective Mitsunobu alkylation of saccharin with various alcohols has been examined. The N/O-alkylation is dependent on the steric hindrance of the alcohols, that is, less sterically hindered alcohol preferentially afford N-alkylated saccharin and vice versa.

  已经研究了糖精与各种醇的区域选择性 Mitsunobu 烷基化。N/O-烷基化取决于醇的空间位阻，即空间位阻较小的醇优先提供N-烷基化糖精，反之亦然。
• Compositions useful as inhibitors of voltage-gated sodium channels
  申请人：Gonzalez E. Jesus

  公开号：US20060025415A1

  公开（公告）日：2006-02-02

  The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及用作电压门控钠通道抑制剂的化合物。本发明还提供了包含本发明化合物的药学上可接受的组合物以及使用这些组合物治疗各种疾病的方法。
• SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Nuss John N.

  公开号：US20090060912A1

  公开（公告）日：2009-03-05

  Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

  提供了化学式I的化合物，其中变量具有所述的值。药物制剂包括该化合物或其药学上可接受的盐以及药学上可接受的载体和其他药物的组合。治疗患者的方法包括向需要该制剂的患者给予本发明的药物制剂。
• Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels
  申请人：Gonzalez, III Jesus E.

  公开号：US20100087479A1

  公开（公告）日：2010-04-08

  The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及一种作为电压门控钠离子通道抑制剂有用的化合物。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗各种疾病的方法。